Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 36,608 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $8.56, for a total value of $313,364.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Thursday, August 31st, Hbm Healthcare Investments (Ca sold 639 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $9.50, for a total value of $6,070.50.
  • On Monday, August 7th, Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $186,795.00.
  • On Tuesday, August 8th, Hbm Healthcare Investments (Ca sold 19,803 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $207,931.50.
  • On Friday, July 28th, Hbm Healthcare Investments (Ca sold 6,585 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total value of $69,208.35.
  • On Monday, July 24th, Hbm Healthcare Investments (Ca sold 160 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $1,680.00.
  • On Thursday, July 20th, Hbm Healthcare Investments (Ca sold 44,231 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $464,425.50.
  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total value of $734,165.54.
  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.53, for a total value of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.52, for a total value of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total value of $19,418.50.

Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 0.12% during trading on Thursday, hitting $8.49. The stock had a trading volume of 12,989 shares. The company’s market cap is $227.85 million. The company’s 50 day moving average is $9.21 and its 200-day moving average is $10.28. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $12.75.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. On average, equities research analysts predict that Nabriva Therapeutics AG will post ($2.28) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Major Shareholder Sells $313,364.48 in Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/nabriva-therapeutics-ag-nbrv-major-shareholder-sells-313364-48-in-stock.html.

Several large investors have recently bought and sold shares of the stock. Wellington Management Group LLP increased its holdings in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after purchasing an additional 193,951 shares during the last quarter. Almanack Investment Partners LLC. increased its holdings in shares of Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after purchasing an additional 751,366 shares during the last quarter. Nationwide Fund Advisors increased its holdings in shares of Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares during the last quarter. 68.56% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have issued reports on NBRV shares. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Thursday, August 10th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Nabriva Therapeutics AG in a research note on Monday, August 28th. Cantor Fitzgerald started coverage on Nabriva Therapeutics AG in a research note on Thursday, June 22nd. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, ValuEngine downgraded Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. Nabriva Therapeutics AG currently has a consensus rating of “Buy” and a consensus target price of $16.25.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.